Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...

By Yahoo! Finance   |   1 month ago
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...

CEO Sean Singh is confident that data from Palisade 3 and 4 will be available in 2025 without any delays. He assures that there are no concerns regarding study execution, with enhancements made and a strong team in place, ensuring protocol adherence and reduced reliance on CRO surveillance.

Read More

Did you find this insightful?